SHR4640 not checked

Hengrui

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
8 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Primary Gout and Hyperuricemia
Main trialPhase 2
“SHR4640 tablets is a highly selective and potent URAT1 inhibitors. The study is being conducted to evaluate the efficacy, and safety of SHR4640 tablet combined with 40 mg/d febuxostat tablet in reducing uric acid in subjects with primary gout and hyperuricemia The primary purpose of the study is to evaluate the efficacy and safety of the combination of SHR4640 and 40 mg/d febuxostat compared with 60 mg/d febuxostat in primary gout and hyperuricemia subjects with inadequate control on 40 mg/d febuxostat for 12 weeks.”In the company’s words, NCT07362355 on ClinicalTrials.gov

Other drugs for Primary Gout and Hyperuricemia

All 11 drugs for Primary Gout and Hyperuricemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Jul 2027 The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
Phase 3Completed 14 Jul 2021 A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
Phase 3Completed 13 Dec 2023 A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
Phase 2Unknown 30 May 2023 Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
Phase 1Completed 5 Sep 2021 Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
Phase 1Unknown Dec 2022 Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
Phase 1Completed 13 Jan 2024 Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
Phase 1Completed 1 Jul 2024 Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SHR4640

Following is part of Solo: you see every change to SHR4640 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in